-
A Case Study: How England Implemented Its First Population Health Agreement
Sep 9, 2025, 16:22 PM -
Data Reliability in Retrospective Chart Review Studies: Results and Considerations From a Novel Data Review Methodology
Sep 9, 2025, 16:22 PM -
Factors Impacting GKV Rebates for Orphan Drugs (OD) in Germany: A Decision Analysis Using the CRA RADAR Database
Sep 9, 2025, 16:22 PM -
Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain
Sep 9, 2025, 16:22 PM -
A Cross-Sectional Analysis of Early Access Programs in NICE Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis
Sep 9, 2025, 16:22 PM -
Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews
Sep 9, 2025, 16:22 PM -
Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care
Sep 9, 2025, 16:22 PM -
Cross-Agency Analysis of Six-Minute Walk Test (6MWT) Adoption in Muscular and Nonmuscular Neurological HTA Submissions: Assessing Surrogate Endpoints for Disease Progression
Sep 9, 2025, 16:22 PM -
Are Women’s Health Strategies Driving Change? A Review of NICE and SMC HTAs
Sep 9, 2025, 16:22 PM -
Director Primary Data Collection
Sep 9, 2025, 16:22 PM -
Integrating CEUS in Diagnostic Pathways: Evidence of Economic and Organizational Sustainability From the Italian Healthcare System
Sep 9, 2025, 16:22 PM -
Developing the Next Generation of Therapeutics: The Role of Early Model-Based Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Assessing the Feasibility of the Implementation of a Subscription Model Pricing Solution Aimed at Broadening Access to All Eligible Patients Within the HER2 Indication
Sep 9, 2025, 16:22 PM -
The Long-Term Cost-Effectiveness of Insulin Icodec vs. Once-Daily Basal Insulin Analogs in Italy
Sep 9, 2025, 16:22 PM -
Understanding Heterogeneity in the Classification of Locally Advanced Cancer: Analysis of Clinical Trial Records From the Past 2 Years (2023-2025)
Sep 9, 2025, 16:22 PM -
Characterizing Medicines Reimbursed Under Managed Access Protocols in Ireland (2006-2025)
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
Tocilizumab vs. Sarilumab Among Adults Hospitalized Due to COVID-19: A Federated Comparative Effectiveness Study Across England and Scotland Under the Target Trial Emulation Framework
Sep 9, 2025, 16:22 PM -
Evaluating GenAI for HTA Analogue Analysis: Identifying Rare Disease Approvals With Surrogate Endpoints and Single-Arm Trials
Sep 9, 2025, 16:22 PM
